American Journal of BioMedicine Volume 2, Issue 10, pages 1095-1109 October 2014
Brian S. Singer; Stefan K Blinov
Abstract
Ebola was first reported in 1976 in Sudan and Congo and named after the river where it was identified. They cause fulminating disease characterized by acute fever followed by generalized hemorrhagic syndrome that is associated with 90% mortality in the most severe forms. It was later reported in Gabon, Central Africa and between 2 and 4 August 2014, a total of 108 new cases of Ebola virus disease (EVD) (laboratory-confirmed, probable, and suspect cases) as well as 45 deaths were reported from Guinea, Liberia, Nigeria, and Sierra Leone. Surveillance and response represent the final crucial steps in achieving effective control of Ebola virus disease, it should be followed by an effective public health response – delivered as integrated packages – with the purpose to interrupt transmission in well defined areas. In addition, intensive efficacy and pharmacovigilance assessment of these interventions including diagnostics, drugs and vaccines against Ebola and other emerging infectious diseases including NTDs must be carefully re-evaluated, and the cut-offs determined and monitored over time, in addition to enhance cross-border collaboration and strengthen effective coordination across African government and populations. Control interventions were very successful in containing the epidemic of EVD.
Keywords: Ebola virus disease; Hemorrhagic syndrome; Public health; Central Africa
Limited Access HTML Full Text-PDF Feedback
References
1. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377:849–862. [PubMed]
2. Baskerville A, Bowen ET, Platt GS, McArdell LB, Simpson DI. The pathology of experimental Ebola virus infection in monkeys. J. Pathol 1978;125:131-138. [PubMed]
3. Weik M, Modrof J, Klenk H-D, Becker S, Mühlberger E. Ebola virus VP30-mediated transcription is regulated by RNA secondary structure formation. J. Virol 2002;76:8532–8539. [Abstract/ Full-Text]
4. Shabman RS, Hoenen T, Groseth A, Jabado O, Binning JM, Amarasinghe GK, Feldmann H, Basler CF. An upstream open reading frame modulates Ebola virus polymerase translation and virus replication. PLoS Pathog 2013;9:e1003147. [PubMed]
5. Zhou XN. Prioritizing research for “One health – One world” Infect Dis Poverty 2012;1:1. [PubMed]
6. WHO. Ebola virus disease, West Africa-update (31st July). Disease Outbreak News. 2014. [http://www.who.int/csr/don/2014_07_31_ebola/en/]
7. Tambo E, Lin A, Xia Z, Jun-Hu C, Wei H, Robert B, Jia-Gang G, Jürg U, Marcel T, Xiao-Nong Z. Surveillance-response systems: the key to elimination of tropical diseases. Infect Dis Poverty 2014;3:17. [PubMed]
8. Anderson R, Hollingsworth TD, Truscott J, Brooker S. Optimisation of mass chemotherapy to control soil-transmitted helminth infection. Lancet 2012;2(9813):289–290. [PubMed]
9. Perry HN, McDonnell SM, Alemu W, Nsubuga P, Chungong S, Otten MW Jr, Lusamba-dikassa PS, Thacker SB. Planning an integrated disease surveillance and response system: a matrix of skills and activities. BMC Med 2007;2:24. [PubMed]
10. Francis Kasolo JBR, Helen P, editor. World Health Organization, Centers for Disease Control and Prevention. Tchnical guiances for intergrated disease surveillance and response in the African region. 2. Brazzaville: Republic of Congo and Atlanta, USA; 2010. pp. 1–398.
11. Bergquist R, Whittaker M. Strengthening control of neglected tropical diseases in the Asia Pacific region: implications for health information priorities. Inf Dis Poverty 2012;2(1):4. [PubMed]
12. Katz R, Hate V, Kornblet S, Fischer JE. Costing framework for international health regulations (2005). Emerg Inf Dis 2012;2(7):1121–1127. [PubMed]
13. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 2000;6(8):886-9. [PubMed]
14. Sanchez A, Kiley MP, Holloway BP, Auperin DD. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res 1993;29:215–240. [PubMed]
15. Zampieri CA, Fortin JF, Nolan GP, Nabel GJ. The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity. J Virol 2007;81(3):1230-40. [PubMed]
16. Neumann G, Watanabe S, Kawaoka Y. Characterization of Ebolavirus regulatory genomic regions. Virus Res 2009; 144:1–7. [PubMed]
17. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000;408(6812):605-9. [PubMed]
18. Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, Custers JH, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006;3(6):e177. [PubMed]
